| Pharmaceutical Information |
| Drug Name |
Mebeverine |
| Drug ID |
BADD_D01354 |
| Description |
Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms. |
| Indications and Usage |
Not Available |
| Marketing Status |
approved; investigational |
| ATC Code |
A03AA04 |
| DrugBank ID |
DB12554
|
| KEGG ID |
D08160
|
| MeSH ID |
C005096
|
| PubChem ID |
4031
|
| TTD Drug ID |
D0VU8Q
|
| NDC Product Code |
Not Available |
| UNII |
7F80CC3NNV
|
| Synonyms |
mebeverine | 4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate | duspatalin | spasmotalin | mebeverine hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C25H35NO5 |
| CAS Registry Number |
3625-06-7 |
| SMILES |
CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
